November 19, 2021
|
December 2, 2021
|
December 22, 2023
|
February 12, 2022
|
March 2027 (Final data collection date for primary outcome measure)
|
|
|
|
- Phase 2 and 3: Incidence of treatment-emergent adverse events (TEAEs), immune-related AEs, treatment-related AEs, serious AEs, AEs leading to death, AEs leading to dose delays, and AEs leading to discontinuation of study treatment [ Time Frame: Phase 2 up to 27 months, Phase 3 up to 60 months ]
- Phase 2 and 3: Progression-free survival per RECIST v1.1 and iRECIST as assessed by the investigator [ Time Frame: Phase 2: up to 27 months, Phase 3: up to 60 months ]
- Phase 3: Progression-free survival per RECIST v1.1 as assessed by blinded IRC [ Time Frame: Up to 60 months ]
- Phase 2 and 3: Overall Survival as time from randomization to death from any cause [ Time Frame: Phase 2 up to 27 months, Phase 3 up to 60 months ]
- Phase 2 and 3: Overall Response Rate [ Time Frame: Phase 2 up to 27 months, Phase 3 up to 60 months ]
measured by the proportion of patients with best overall response (BOR) of partial response (PR) or complete response (CR) by REICST v1.1 or , immune-based PR (iPR) or immune-based by iRECIST
- Phase 2 and 3: Duration of response (DOR) defined by time from the first objective response of PR or PR until disease progression or death [ Time Frame: Phase 2 up to 27 months, Phase 3 up to 60 months ]
- Phase 2 and 3: Clinical benefit rate (CBR) as defined by the proportion of patients with best overall response of stable disease (SD), PR or CR using RECIS v1.1 or immune-based SD (iSD), iPR, or iCR by iRECIST. [ Time Frame: Phase 2 up to 27 months, Phase 3 up to 60 months ]
- Phase 2 and 3: Deepening of Response the proportion of patients who have a BOR of SD or PR during the VPS and who convert from SD to PR or CR, or from PR to CR after start of the study treatment and/or SOC maintenance treatment in the STS per RECIST v1.1 [ Time Frame: Phase 2 up to 27 months, Phase 3 up to 60 months ]
VPS = Vaccine Production Stage; STS = Study Treatment Stage
- Phase 2 and 3: The feasibility of manufacturing a patient-specific vaccine defined by the proportion of patients for whom vaccine was successfully manufactured from those randomized to the vaccine arm. [ Time Frame: Study Treatment Screening visit (up to 28 days before Day 1 of study drug administration) ]
|
- Phase 2 and 3: Incidence of adverse events (AEs), immune-related AEs, treatment-related AEs, serious AEs, AEs leading to death, AEs leading to dose delays, and AEs leading to discontinuation of study treatment [ Time Frame: Phase 2 up to 27 months, Phase 3 up to 60 months ]
- Phase 2 and 3: Progression-free Survival per RECIST v1.1 and iRECIST as assessed by the investigator [ Time Frame: From time of randomization until disease progression or death from any cause (Phase 2: up to 27 months, Phase 3: up to 60 months) ]
- Phase 3: Progression-free Survival per RECIST v1.1 as assessed by blinded IRC [ Time Frame: From time of randomization until disease progression or death from any cause (up to 60 months) ]
- Phase 2 and 3: Overall Survival [ Time Frame: Phase 2 up to 27 months, Phase 3 up to 60 months ]
- Phase 2 and 3: Overall Response Rate [ Time Frame: Phase 2 up to 27 months, Phase 3 up to 60 months ]
Response measured by number of patients with best response of Partial Response (PR), immune-base PR (iPR), Complete Response (CR), or iCR.
- Phase 2 and 3: Duration of Response [ Time Frame: From time of first response until disease progression (Phase 2 up to 27 months, Phase 3 up to 60 months) ]
- Phase 2 and 3: Clinical Benefit Rate (CBR) [ Time Frame: Phase 2 up to 27 months, Phase 3 up to 60 months ]
CBR measured by number of patients who have achieved Stable Disease (SD), iSD, PR, iPR, CR, or iCR.
- Phase 2 and 3: Deepening of Response [ Time Frame: From time of first response (SD or PR) until conversion to PR or CR (Phase 2 up to 27 months, Phase 3 up to 60 months) ]
Deepening of response measured by number of patients with SD or better response to routine therapy who convert from SD to PR or from PR to CR.
- Phase 2 and 3: Success of Vaccine Manufacture [ Time Frame: Study Treatment Screening visit (up to 28 days before Day 1 of study drug administration) ]
Vaccine manufacture success measured by the number of patients having sufficient neoantigens identified to warrant vaccine production.
|
Not Provided
|
Not Provided
|
|
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
|
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
|
The primary objective of the Phase 2 portion of the study is to characterize the clinical activity of maintenance therapy with GRT-C901/GRT-R902 (patient-specific vaccines) in combination with checkpoint inhibitors in addition to fluoropyrimidine/bevacizumab versus a fluoropyrimidine/bevacizumab alone as assessed by molecular response which is based on changes in circulating tumor (ct)DNA. The primary objective of the Phase 3 portion is to demonstrate clinical efficacy of the regimen as assessed by progression-free survival.
|
Tumors harboring non-synonymous deoxyribonucleic acid (DNA) mutations can present peptides containing these mutations as non-self antigens in the context of human leukocyte antigens (HLAs) on the tumor cell surface. A fraction of mutated peptides result in neoantigens capable of generating T-cell responses that exclusively target tumor cells. Sensitive detection of these mutations allows for the identification of neoantigens unique to each patient's tumor to be included in a patient-specific cancer vaccine that targets these neoantigens. This vaccine regimen uses two vaccine vectors as a heterologous prime/boost approach (GRT-C901 first followed by GRT-R902) to stimulate an immune response. This study will explore the anti-tumor activity of this patient-specific immunotherapy in combination with checkpoint inhibitors in addition to fluoropyrimidine/bevacizumab.
|
Interventional
|
Phase 2 Phase 3
|
Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment
|
Colorectal Neoplasms
|
- Drug: GRT-C901
A patient-specific neoantigen cancer vaccine administered via intramuscular (IM) injection as prime and single boost at a dose of 1x10^12 viral particles 2 times over the course of the first year.
- Drug: GRT-R902
A patient-specific neoantigen cancer vaccine boost, administered via IM injection at a dose of 30ug 4 times over the course of the first year.
- Drug: Atezolizumab
Atezolizumab will be administered via intravenous (IV) infusion at a dose of 1680 mg once every 4 weeks.
Other Name: Tecentriq
- Drug: Ipilimumab
Ipilimumab will be administered via subcutaneous (SC) injection at a dose of 30 mg with the first dose of GRT-C901 and GRT-R902.
Other Name: Yervoy
- Drug: Fluoropyrimidine plus leucovorin
Fluoropyrimidine (infusional 5-FU or capecitabine) and leucovorin administered as maintenance therapy per standard of care.
Other Name: Xeloda
- Drug: Bevacizumab
Bevacizumab administered as maintenance therapy per standard of care.
Other Name: Avastin
|
- Experimental: Vaccine Arm
After receiving up to 24 weeks induction therapy with a fluoropyrimidine/oxaliplatin/bevacizumab (with or without irinotecan), per standard of care and after completing vaccine production screening, patients will receive a total of 6 administrations of GRT-C901/GRT-R902 plus ipilimumab co-administered only with the first dose of GRT-C901 and GRT-R902. All patients will receive atezolizumab in addition to maintenance therapy of a fluoropyrimidine and bevacizumab according to standard of care.
Interventions:
- Drug: GRT-C901
- Drug: GRT-R902
- Drug: Atezolizumab
- Drug: Ipilimumab
- Drug: Fluoropyrimidine plus leucovorin
- Drug: Bevacizumab
- Active Comparator: Control Arm
After receiving up to 24 weeks induction therapy with a fluoropyrimidine/oxaliplatin/bevacizumab (with or without irinotecan), per standard of care and undergoing vaccine production screening, patients will receive maintenance therapy of a fluoropyrimidine and bevacizumab according to standard of care.
Interventions:
- Drug: Fluoropyrimidine plus leucovorin
- Drug: Bevacizumab
|
Not Provided
|
|
Active, not recruiting
|
700
|
665
|
March 2027
|
March 2027 (Final data collection date for primary outcome measure)
|
Inclusion Criteria:
- Patients with histologically confirmed metastatic colorectal cancer (CRC) who are planned for, or have received <30 days of first-line treatment in the metastatic setting with FOLFOX/bev, CAPEOX/bev, FOLFOXIRI/bev, or CAPOXIRI/bev per SOC
- Measurable and unresectable metastatic disease according to RECIST v1.1
- Availability of formalin-fixed paraffin-embedded (FFPE) tumor specimens.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Patient has adequate organ function per defined criteria
- If women of childbearing potential (WCBP), must be willing to undergo pregnancy testing and agrees to the use at least 1 highly effective contraceptive method during the study treatment period and for 150 days after last investigational study treatment.
Exclusion Criteria:
- Patients with deficient mismatch repair (dMMR) or microsatellite instability (MSI-H) phenotype
- Patient has a known tumor mutation burden <1 non-synonymous mutations/megabase
- Known DNA Polymerase Epsilon mutations
- Patients with known BRAFV600E mutations
- Bleeding disorder or history of significant bruising or bleeding following IM injections or blood draws
- Immunosuppression anticipated at time of study treatment
- History of allogeneic tissue/solid organ transplant
- Active or history of autoimmune disease or immune deficiency
- Patient with symptomatic or actively progressing central nervous system (CNS) metastases, carcinomatous meningitis, or has been treated with whole brain radiation
- History of other cancer within 2 years with the exception of neoplasm that has undergone potentially curative therapy
- Any severe concurrent non-cancer disease that, in the judgment of the Investigator, would make the patient inappropriate for the current study
- Active tuberculosis or recent (<2 weeks) clinically significant infection, evidence of active hepatitis B or hepatitis C, or known history of positive test for HIV
- History of pneumonitis requiring systemic steroids for treatment (with the exception of prior resolved in-field radiation pneumonitis)
- Myocardial infarction within previous 3 months, unstable angina, serious uncontrolled cardiac arrhythmia, history of myocarditis, or congestive heart failure (Class III or IV).
- Pregnant, planning to become pregnant, or nursing.
|
Sexes Eligible for Study: |
All |
|
18 Years and older (Adult, Older Adult)
|
No
|
Contact information is only displayed when the study is recruiting subjects
|
United States
|
|
|
NCT05141721
|
GO-010
|
Yes
|
Studies a U.S. FDA-regulated Drug Product: |
Yes |
Studies a U.S. FDA-regulated Device Product: |
No |
|
|
Gritstone bio, Inc.
|
Same as current
|
Gritstone bio, Inc.
|
Same as current
|
Not Provided
|
Not Provided
|
Gritstone bio, Inc.
|
April 2023
|